M. Sliwkowski

Oncology · 2001–2012

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 20 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 102 citations into it; #79 of 1,698 by trust here, #152 by citations
• Radiology, Nuclear Medicine and Imaging — 59 citations into it; #406 of 3,265 by trust here, #133 by citations
• Molecular Biology — 54 citations into it; #3,157 of 17,773 by trust here, #4,078 by citations

Whom M. Sliwkowski trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Y. Yarden

Who trusts M. Sliwkowski overall

1. M. Lacouture
2. J. Baselga
3. Waltraud X. Schulze
4. Gopalakrishnan Bulusu
5. C. Yun
6. M. Moasser
7. Carlos L. Arteaga
8. N. Hynes
9. Y. Yarden
10. William W. Chen

Papers from M. Sliwkowski's perspective

Ordered by how strongly the researchers M. Sliwkowski trusts endorse each paper. Same corpus, a different order for every researcher.

1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
2. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
3. Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
4. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
5. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
6. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
7. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. (Molecules and Cells)
8. Trastuzumab--mechanism of action and use in clinical practice. (New England Journal of Medicine)
9. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation (Proceedings of the National Academy of Sciences of the United States of America)
10. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. (Journal of Clinical Oncology)

Their papers

• Untangling the ErbB signalling network (2001) — 7,035 citations
• Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (2009) — 874 citations
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (2012) — 928 citations
• Treatment of HER2-positive breast cancer: current status and future perspectives (2012) — 878 citations
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (2008) — 1,596 citations
• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (2008) — 1,242 citations
• A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. (2008) — 683 citations
• Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (2004) — 1,125 citations
• An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. (2003) — 955 citations
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* (2002) — 1,329 citations
• Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (2002) — 910 citations